Literature DB >> 20566895

Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation.

Pablo Bartolucci1, Vicky Chaar, Julien Picot, Dora Bachir, Anoosha Habibi, Christine Fauroux, Frédéric Galactéros, Yves Colin, Caroline Le Van Kim, Wassim El Nemer.   

Abstract

Sickle cell disease is characterized by painful vaso-occlusive crises during which abnormal interactions between erythroid adhesion molecules and vessel-wall proteins are thought to play a critical role. Hydroxyurea, the only drug with proven benefit in sickle cell disease, diminishes these interactions, but its mechanism of action is not fully understood. We report that, under hydroxyurea, expression of the unique erythroid laminin receptor Lu/BCAM was increased, but red blood cell adhesion to laminin decreased. Because Lu/BCAM phosphorylation is known to activate cell adhesion to laminin, it was evaluated and found to be dramatically lower in hydroxyurea-treated patients. Analysis of the protein kinase A pathway showed decreased intracellular levels of the upstream effector cyclic adenosine monophosphate during hydroxyurea treatment. Using a cellular model expressing recombinant Lu/BCAM, we showed that hydroxyurea led to decreased intracellular cyclic adenosine monophosphate levels and diminished Lu/BCAM phosphorylation and cell adhesion. We provide evidence that hydroxyurea could reduce abnormal sickle red blood cell adhesion to the vascular wall by regulating the activation state of adhesion molecules independently of their expression level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566895     DOI: 10.1182/blood-2009-12-257444

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy.

Authors:  Jamie L Maciaszek; Biree Andemariam; Krithika Abiraman; George Lykotrafitis
Journal:  Biophys J       Date:  2014-03-18       Impact factor: 4.033

Review 2.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

3.  Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is Revealed by AFM.

Authors:  Jing Zhang; Krithika Abiraman; Sasia-Marie Jones; George Lykotrafitis; Biree Andemariam
Journal:  Biophys J       Date:  2017-01-10       Impact factor: 4.033

4.  The Gardos effect drives erythrocyte senescence and leads to Lu/BCAM and CD44 adhesion molecule activation.

Authors:  Thomas R L Klei; Jill J Dalimot; Boukje M Beuger; Martijn Veldthuis; Fatima Ait Ichou; Paul J J H Verkuijlen; Iris M Seignette; Peter C Ligthart; Taco W Kuijpers; Rob van Zwieten; Robin van Bruggen
Journal:  Blood Adv       Date:  2020-12-22

5.  Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.

Authors:  Vicky Chaar; Sandrine Laurance; Claudine Lapoumeroulie; Sylvie Cochet; Maria De Grandis; Yves Colin; Jacques Elion; Caroline Le Van Kim; Wassim El Nemer
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

Review 6.  Blood rheology biomarkers in sickle cell disease.

Authors:  Madeleine Lu; Minke Ae Rab; Sergey S Shevkoplyas; Vivien A Sheehan
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-16

7.  Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.

Authors:  Sandrine Laurance; Pauline Lansiaux; François-Xavier Pellay; Michelle Hauchecorne; Arndt Benecke; Jacques Elion; Claudine Lapoumeroulie
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

8.  Dimerization and phosphorylation of Lutheran/basal cell adhesion molecule are critical for its function in cell migration on laminin.

Authors:  Anna Guadall; Sylvie Cochet; Olivier Renaud; Yves Colin; Caroline Le Van Kim; Alexandre G de Brevern; Wassim El Nemer
Journal:  J Biol Chem       Date:  2019-08-14       Impact factor: 5.157

9.  Insights into determinants of spleen injury in sickle cell anemia.

Authors:  Sara El Hoss; Sylvie Cochet; Mickaël Marin; Claudine Lapouméroulie; Michael Dussiot; Naïm Bouazza; Caroline Elie; Mariane de Montalembert; Cécile Arnaud; Corinne Guitton; Béatrice Pellegrino; Marie Hélène Odièvre; Frédérique Moati; Caroline Le Van Kim; Yves Colin Aronovicz; Wassim El Nemer; Valentine Brousse
Journal:  Blood Adv       Date:  2019-08-13

10.  Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Authors:  Ofelia Alvarez; Nancy A Yovetich; J Paul Scott; William Owen; Scott T Miller; William Schultz; Alexandre Lockhart; Banu Aygun; Jonathan Flanagan; Melanie Bonner; Brigitta U Mueller; Russell E Ware
Journal:  Am J Hematol       Date:  2013-08-30       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.